Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Feb 15, 2022; 14(2): 533-542
Published online Feb 15, 2022. doi: 10.4251/wjgo.v14.i2.533
Endoscopic ultrasound-guided ablation of solid pancreatic lesions: A systematic review of early outcomes with pooled analysis
Marco Spadaccini, Milena Di Leo, Andrea Iannone, Daan von den Hoff, Alessandro Fugazza, Piera Alessia Galtieri, Gaia Pellegatta, Roberta Maselli, Andrea Anderloni, Matteo Colombo, Peter D Siersema, Silvia Carrara, Alessandro Repici
Marco Spadaccini, Milena Di Leo, Alessandro Fugazza, Piera Alessia Galtieri, Gaia Pellegatta, Roberta Maselli, Andrea Anderloni, Matteo Colombo, Silvia Carrara, Alessandro Repici, Endoscopic Unit, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano 20089, Milan, Italy
Marco Spadaccini, Roberta Maselli, Alessandro Repici, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele 20090, Milan, Italy
Andrea Iannone, Endoscopy Unit, Azienda Ospedale Policlinico, Bari 70124, Italy
Daan von den Hoff, Peter D Siersema, Endoscopy Unit, Radboud University Medical Center, Nijmegen 6525 GA, Netherlands
Author contributions: Spadaccini M drafted the manuscript; Spadaccini M, Di Leo M, Iannone A, Fugazza A, Galtieri PA, Pellegatta G, Maselli R, Anderloni A, Colombo M, Siersema PD, Carrara S, and Repici A conducted the analyses and interpretation of the data; Di Leo M, Iannone A, von den Hoff D, Fugazza A, Galtieri PA, Pellegatta G, Maselli R, Anderloni A, Colombo M, Siersema PD, Carrara S, and Repici A made critical revisions related to the important intellectual content of the manuscript; All authors made substantial contributions to the conception and design of the study, acquisition of data, and final approval of the version of the article to be published.
Conflict-of-interest statement: All the authors declare that they have no competing interests related to the topic.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
http://creativecommons.org/Licenses/by-nc/4.0/ Corresponding author: Silvia Carrara, MD, Doctor, Professor, Endoscopic Unit, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano 20089, Milan, Italy.
silvia.carrara@hunimed.eu
Received: February 22, 2021
Peer-review started: February 22, 2021
First decision: April 19, 2021
Revised: April 27, 2021
Accepted: December 31, 2021
Article in press: December 31, 2021
Published online: February 15, 2022
Processing time: 352 Days and 16.8 Hours
ARTICLE HIGHLIGHTS
Research background
Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is emerging as a complementary therapeutic approach for pancreatic solid masses.
Research motivation
Results of published data are difficult to interpret because of a retrospective design and small sample size.
Research objectives
The aim of this paper was to systematically review data on EUS-RFA for solid lesions and to pool the results of the different experiences in order to have a more reliable point of view.
Research methods
A comprehensive systematic literature search on the main databases was performed to identify articles in which patients with pancreatic solid lesions underwent EUS-RFA.
Research results
The pooled technical success rate was 99.0% (I2: 25.82%). The pooled overall adverse event (AE) rate was 8.0% (I2: 11.46%). Excluding mild AEs, the serious AE pooled rate was 1.0% (I2: 0%). No mortality related to the procedure was reported.
Research conclusions
The present pooled analysis confirms the safety and feasibility of the EUS-guided RFA.
Research perspectives
Further studies with longer follow-up are necessary to properly evaluate the clinical efficacy as a stand-alone approach or as a part of multimodality management of pancreatic neoplasia.
